Yes, you can use an HSA for PRP and stem cell therapy when you are treating a real degenerative condition such as osteoarthritis or severe tendon damage. Under IRS Code Section 213(d), HSA use does not depend on your insurer’s approval. The trap is non-compliant allogeneic products, made from donor tissue. They can disqualify the expense. Autologous PRP or bone marrow concentrate, made from your own body and backed by a Letter of Medical Necessity, avoids it.
You asked about platelet-rich plasma. You asked about bone marrow concentrate. You asked about real healing treatment for a long-term, wear-and-tear problem. And your insurance company gave you the answer it always gives: not covered, denied.
That denial leaves something out. The federal government uses a different standard. And a Health Savings Account follows the federal rule, not your insurance plan’s rule.
This article explains both halves of that. One is the opportunity. The other is the rule trap most regenerative clinics ignore.
A necessary framing before anything else: this is educational information, not medical, tax, legal, or financial advice. HSA eligibility depends on your individual medical circumstances, documentation, and tax situation. Rules change. Confirm your own eligibility with your plan administrator and a qualified tax or financial professional before spending HSA funds on anything.
Two different questions being confused for one
When your insurer denies PRP, it is answering a narrow question: will this company pay for this? A private company makes that call using its own coverage rules.
The HSA question is a different one: does this cost count as a medical expense under federal tax law?
Under IRS Code Section 213(d), a Health Savings Account can pay for treatments that diagnose, cure, mitigate, or treat a real disease or structural defect. The IRS does not tie that to what your insurance company approves. Different bodies make the two decisions under different rules. One does not control the other.
Say you are treating a real wear-and-tear condition, such as osteoarthritis or severe tendon damage. Then orthobiologic treatment can count as a medical expense. You can pay for it with 100 percent pre-tax dollars.
That makes a big difference in the real cost of care. Most patients never learn it exists. The denial letter reads like a final ruling. It is really one company’s coverage choice.
The compliance trap
Here is the part that gets skipped, and it is the part that carries real financial risk.
The rule above depends on the treatment being what it claims to be, given lawfully. Some clinics use non-compliant allogeneic products. These are made from a donor’s tissue, not from you. They do not meet the rules of 21 CFR Part 1271, the federal rule for products made from human cells and tissue.
When the product itself is non-compliant, the expense can be disqualified.
The result is not a letter asking you to try again. In an IRS audit, HSA spending that does not qualify can be counted as income. That means you owe regular income tax on money you treated as pre-tax, plus a 20 percent penalty.
Read that chain carefully, because of who pays for it. The clinic chose the product. The clinic made the rule decision. The patient carries the tax risk. You can do everything right on your end and still be at risk from a buying choice no one told you about.
Why autologous matters here
That is why the question of where the product comes from is not a small detail.
Autologous orthobiologics come from your own body. PRP comes from your blood. Bone marrow concentrate comes from your own marrow. Using your own material removes the FDA rule risk that comes with non-compliant donor products.
There are two reasons to care about that, and they are worth keeping apart. The medical reasons to use your own material are their own topic. The point here is narrower, and it is about money. The legal status of what is injected decides whether your pre-tax dollars were spent properly.
Maybe you plan to pay for regenerative treatment with HSA funds anywhere. Then ask the clinic directly. Is the product autologous? If not, what is its status under 21 CFR Part 1271? A practice that cannot answer that clearly is a practice whose risk you are carrying.
The audit trail: documentation is the protection
Belief does not make a cost eligible. Records do.
The tool that does this work is a formal Letter of Medical Necessity. It is a doctor’s record that ties the treatment to a diagnosed real disease or structural defect. That is exactly the standard Section 213(d) describes.
There is a gap between a cost that was eligible and a cost you can prove was eligible. You may have to prove it years later, to someone who was not in the room. Those are not the same thing. Only the second one survives an audit.
The part that determines whether any of it was worth paying for
None of the above says anything about whether the treatment will work.
An orthobiologic procedure is an order to repair, and it is delivered into a body. Treating the terrain underneath is what makes the therapy actually work. That means metabolism, nutrition and inflammation. Picture a perfectly recorded, perfectly legal, perfectly funded injection. Put it in a body that cannot carry out the order, and it is still a poor use of your money.
So here is the honest order. First find out whether you are a medical candidate. Then work out how to pay for it. At Regen.MD the first step is a Clinical Evaluation. That is where we decide whether any orthobiologic therapy is right for you. A payment method does not decide it.
Regen.MD is located at 4477 Woodson Rd, Suite 103, St. Louis, MO 63134, next to St. Louis Lambert International Airport, serving the St. Louis metro including St. Louis County, St. Charles, Clayton, and Florissant.
Frequently asked questions
My insurance denied PRP as experimental. Does that make it HSA-ineligible?
Not automatically. They are separate decisions. IRS Code Section 213(d) allows HSA funds for treatments that diagnose, cure, mitigate, or treat a real disease or structural defect. The IRS does not tie eligibility to your insurance company’s coverage decision. Whether your own situation qualifies is a question for your plan administrator and a qualified tax professional, not for a clinic or a website.
What is the actual risk if an expense is disqualified?
In an IRS audit, HSA spending that does not qualify can be counted as income, with a 20 percent penalty on top. The cause cited most often is a clinic using non-compliant donor products under 21 CFR Part 1271. The clinic makes that decision. The money penalty lands on the patient.
What documentation should I have?
A formal Letter of Medical Necessity from the treating physician. It links the treatment to a diagnosed disease or structural defect. Confirm with your plan administrator or tax advisor what your specific plan and situation require, since documentation standards and rules can change.
Should I stop other treatment to pursue an orthobiologic procedure I can fund this way?
No. Do not start, stop, or change any treatment without consulting your physician. Having the money is not a medical reason. An evaluation decides whether you are a candidate. Orthobiologic therapies are not covered by insurance for these indications, individual results vary, and not every patient is appropriate for them.
Key takeaways
- Your insurer’s “experimental” label and the IRS meaning of a qualified medical expense are two separate standards. Two separate bodies apply them.
- Under IRS Code Section 213(d), HSA funds can pay for treatment of a real disease or structural defect. That may mean 100 percent pre-tax dollars.
- Clinics that use non-compliant donor products under 21 CFR Part 1271 can cause your expense to be disqualified.
- In an audit, an expense that does not qualify can be counted as income, plus a 20 percent penalty. The patient carries the risk for the clinic’s product choice.
- Orthobiologics made from your own body remove the FDA rule risk. A formal Letter of Medical Necessity lets you prove eligibility, not just claim it.
This article is educational and is not medical, tax, legal, or financial advice, and is not a substitute for evaluation, diagnosis, or treatment by a physician. HSA eligibility depends on your individual medical circumstances, documentation, and tax situation; rules change, and references to IRS code and federal regulations are general in nature and should be independently verified with your plan administrator and a qualified tax or financial professional. Individual results vary, and not every patient is a candidate for the therapies described. Do not start, stop, or change any treatment without consulting your physician.
Find out what is actually driving your pain
Regen.MD begins with a physician-led Clinical Evaluation — a review of your history, imaging, and metabolic data, and a written terrain roadmap. Evaluation is contingent upon review of your data.
Questions? Call or text us.